CIM22LAPP1A-10 is an intermediate-maturing, high-yielding, white maize hybrid with resistance to TSC, MLB and ear rots. The product is notable for its high optimum and rainfed yield, excellent female parent seed yield, semi-dent grain and resistance to root and stalk lodging and is suitable for food use in tropical, rainfed, low-altitude areas in Latin America. |
|
General Information |
|
Target Region |
Latin America |
|
Adaptation/Agroecological zone |
0 - 1200m above sea level |
|
Type of product |
Three-way hybrid |
|
Year first announced |
2024 |
|
|
|
|
Grain Characteristics |
|
Grain color |
White |
|
|
|
Grain texture |
Semi-dent |
Abiotic Stress Performance |
|
|
|
Grain yield under optimum conditions |
8.78 t/ha |
|
Biotic Stress Performance |
Grain yield under rainfed conditions |
4.99 t/ha |
|
Maydis leaf blight (MLB) (1-9)* |
2.5 |
Grain yield on-farm (avg) |
7.24 t/ha |
|
Tar Spot Complex (TSC) (1-9)* |
2.9 |
Grain yield on-farm (opt.) |
9.10 t/ha |
|
Ear Rots (%) |
7.3% |
Grain yield on-farm (rainfed) |
5.48 t/ha |
|
*Scored on 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible |
|
|
|
Agronomic Characteristics |
|
|
|
Maturity group |
Intermediate |
|
Seed Production Characteristics |
50% anthesis |
57 DAP |
|
SC female parent seed yield |
7.9 t/ha |
Plant height |
244 cm |
|
Male seed yield |
3.6 t/ha |
Ear height |
127 cm |
|
Nicking |
-6 days |
Ear position (ratio) |
0.52 |
|
|
|
Ears per plant |
1.02 |
|
Comments |
Ear aspect (1-9)* |
4.2 |
|
Product information is based on data from the 2022 CIMMYT LatAm Stage 4 Regional Trials and 2023 Stage 5 Trials. Actual performance will vary depending on a number of agronomic and environmental factors.
Abbreviations:
DAP = days after planting
SC = Single-cross
MLB = Maydis leaf blight
TSC = Tar spot complex |
Plant aspect (1-9)* |
4.6 |
|
Bad husk cover |
4.4% |
|
Root lodging |
2.4% |
|
Stalk lodging |
7.2% |
|
Anther-silking interval |
0.4 days |
|
*Plant and ear aspects are scored on 1-9 scale, where 1 = desirable and 9 = undesirable characteristics |
|
|
|
|
|
Further Links |
|
Full Announcement & trial data |
|
|